Audit of Global Fund Grants in Nigeria
24 March 2022
Global Fund grants in Nigeria are mostly performing well across the three diseases. HIV performance is steadily improving, with treatment figures rising and infections decreasing, while malaria prevalence fell by almost 50% between 2010 and 2018. Tuberculosis (TB) notification has increased and TB treatment has improved. Community interventions, however, are not meeting vulnerable populations’ needs. Urgent attention should be given to interventions for pregnant women, children under 5 years old, adolescents and key populations.
By innovating and adapting, disease programs have continued to function throughout the COVID-19 pandemic. Nigeria’s ability to absorb C19RM funding is low however, limiting its ability to implement key activities and procure commodities promptly.
The Global Fund’s supply chain arrangement in Nigeria similarly needs significant improvement. Since 2016, the organization has contracted Chemonics to provide supply chain services for HIV and malaria commodities. Chemonics’ internal controls are inadequate and we found multiple unexplained variances. Information technology systems do not generate accurate and reliable supply chain data and information.
- Message from the Executive Director: Global Fund Grants in Nigeria
- Global Fund Grants in Nigeria (GF-OIG-22-003 - 24 March 2022)
download in English | Français